Seonix Bio launches polygenic risk score glaucoma test in US
Key takeaways:
- The saliva test evaluates a patient’s genetic variants to determine risk for glaucoma development or progression.
- It is now available in the U.S., Australia and New Zealand.
Editor’s note: This is a developing news story. Please check back soon for updates.
Seonix Bio launched SightScore, a polygenic risk score testing service for primary open-angle glaucoma, in the United States, according to a press release.
SightScore contributes to a more personalized treatment approach by distinguishing between patients who may be at higher or lower risk for glaucoma. The saliva test evaluates a patient’s genetic variants to estimate the risk for developing glaucoma or the risk for progression in those who already have the disease.
Clinicians can prioritize and manage patients appropriately based on their genetic risk, the release said.
“I am incredibly pleased that we are able to make SightScore clinically available in the U.S., marking a significant advancement in the fight against glaucoma,” Nick Haan, CEO of Seonix Bio, said in the release. “In the past, clinical genetic risk assessment for glaucoma has targeted a single gene or tens of genetic variants. As the first truly polygenic clinical genetic risk score for glaucoma on the market, using 7 million genetic variants, SightScore represents a major step forward in how we diagnose and manage this disease. By identifying individuals at high genetic risk through a simple saliva test, we empower clinicians to intervene earlier and ultimately preserve vision.”
SightScore was previously released in Australia and New Zealand.
Read more about